Quick search:
Content Search
Result Content Research
Result Content Research
1 Setback for Polyphor's breast cancer candidate balixafortide
2 Polyphor to extend period for its strategic evaluation by up to four weeks
3 Balixafortide and Eribulin Shows Modest Responses in Patients with HER2-Negative Breast Cancer
4 Polyphor completes recruitment in Phase III trial of balixafortide in metastatic breast cancer
5 FDA Grants Balixafortide Fast Track Designation for Treatment of Metastatic Breast Cancer Subset
6 Balixafortide Plus Eribulin Fails to Improve ORR in Advanced HER2-Negative Breast Cancer
7 Polyphor's Balixafortide Demonstrates Consistent Dual Action Anti-Viral and Anti-Inflammatory Activity in COVID-19 Preclinical
8 Polyphor announces enrollment of first patient in FORTRESS Phase III clinical trial for balixafortide in combination with eribulin in patients with metastatic breast cancer
9 Polyphor Announces Financial Results for the Full-Year 2020 2021-03-05 01:15 ALLSCHWIL, Switzerland
10 Polyphor Announces Closing of Fosun Pharma Licensing
11 Polyphor Temporarily Halts Enrollment in the Phase III Studies of Murepavadin for the Treatment of Patients With Nosocomial Pneumonia
12 Polyphor to Present at the UBS Global Healthcare Virtual Conference
13 Polyphor Hosting Key Opinion Leader Roundtable on Covid-19:
14 Plerixafor for mobilization in stem cell transplantations | JBM
15 Polyphor Receives Approval to Start First-in-Human Clinical Trial of Inhaled Antibiotic Murepavadin
16 Polyphor closes the Phase III PRISM studies of murepavadin intravenous formulation and evaluates further product improvement options
17 Polyphor announces changes to its Board of Directors
18 Polyphor receives award of up to USD $3.3 million from Cystic Fibrosis Foundation to support clinical
19 Multifaceted C-X-C Chemokine Receptor 4 (CXCR4) Inhibition Interferes with Anti–Vascular Endothelial Growth Factor Therapy–Induced Glioma Dissemination
20 November 2013